High real-world incidence of hepatic dysfunction from cabozantinib plus nivolumab for Japanese patients with metastatic renal cell carcinomaToshihide Horiuchi, Koichi Nishimura, Kazutaka Nakamura et al.|Japanese Journal of Clinical Oncology|2025Cited by 1
Safety and efficacy of enfortumab vedotin for locally advanced or metastatic urothelial carcinoma in patients aged 80 years and older: A multicenter retrospective study in JapanYuki Kobari, Toshio Takagi, Junpei Iizuka et al.|Journal of Geriatric Oncology|2025Cited by 1
Efficacy and safety of nivolumab plus cabozantinib in octogenarian patients with advanced renal cell carcinomaYuki Nemoto, Takanori Endo, Hogara Segawa et al.|International Urology and Nephrology|2025Cited by 0
Efficacy and safety of nivolumab plus cabozantinib in octogenarian patients with advanced renal cell carcinomaYuki Nemoto, Tsunenori Kondo, Takanori Endo et al.|Research Square|2024Cited by 0
Association between enfortumab vedotin and renal function in metastatic urothelial carcinoma: A multicenter retrospective study in JapanYuki Kobari, Toshio Takagi, Junpei Iizuka et al.|Research Square|2025Cited by 0